Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Trial Profile

Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Linezolid (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • Focus Therapeutic Use
  • Acronyms ZEPHYR
  • Most Recent Events

    • 05 Jun 2017 Results characterizing resistance patterns in baseline methicillin-resistant Staphylococcus aureus (MRSA) isolates (n=427) presented at the ASM Microbe 2017
    • 18 May 2013 Results of the piggybacked economic analysis in the USA presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 27 Apr 2013 Results of a post-hoc economic analysis in Spain presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top